[go: up one dir, main page]

CN116965919A - Irreversible electroporation ablation method and system with network-management-shaped support structure - Google Patents

Irreversible electroporation ablation method and system with network-management-shaped support structure Download PDF

Info

Publication number
CN116965919A
CN116965919A CN202311111154.3A CN202311111154A CN116965919A CN 116965919 A CN116965919 A CN 116965919A CN 202311111154 A CN202311111154 A CN 202311111154A CN 116965919 A CN116965919 A CN 116965919A
Authority
CN
China
Prior art keywords
atherosclerosis
patient
ablated
ablation
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202311111154.3A
Other languages
Chinese (zh)
Other versions
CN116965919B (en
Inventor
焦君涵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Intelligent Health Co ltd
Original Assignee
Tianjin Intelligent Health Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Intelligent Health Co ltd filed Critical Tianjin Intelligent Health Co ltd
Priority to CN202311111154.3A priority Critical patent/CN116965919B/en
Publication of CN116965919A publication Critical patent/CN116965919A/en
Application granted granted Critical
Publication of CN116965919B publication Critical patent/CN116965919B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/321—Accessories or supplementary instruments therefor, e.g. cord hangers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06—Measuring blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345—Vascular system
    • A61B2018/00351—Heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345—Vascular system
    • A61B2018/00404—Blood vessels other than those in or around the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00613—Irreversible electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00839—Bioelectrical parameters, e.g. ECG, EEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00863—Fluid flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B2018/1405—Electrodes having a specific shape

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Plasma & Fusion (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the field of electroporation ablation, and discloses an irreversible electroporation ablation method and system with a network-management-shaped bracket structure, wherein the method comprises the following steps: analyzing the atherosclerosis risk of the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated; identifying the heart rhythm of the patient to be ablated, and constructing an atherosclerosis evaluation report of the patient to be ablated; identifying an atheromatous mass location and an atheromatous mass area of a patient to be ablated corresponding to the atheromatous mass; pulling the ablation stent to the position of the atherosclerosis mass, and determining the deployment diameter of the network tube of the ablation stent; when the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, current transmission is carried out on the conductive polar plate corresponding to the ablation support, so that ablation electric energy is obtained, the ablation electric energy is converted into ablation heat energy, the atherosclerosis is ablated, and an ablation result of a patient to be ablated is obtained. The invention can improve the ablation effect of the ablation support on abnormal tissues of a patient to be ablated.

Description

Irreversible electroporation ablation method and system with network-management-shaped support structure
Technical Field
The invention relates to the field of electroporation ablation, in particular to an irreversible electroporation ablation method and system with a network-management-shaped support structure.
Background
Electroporation ablation refers to a technical means of treating heart diseases, particularly arrhythmias, by ablating abnormal heart tissue or eliminating abnormal electrical signals, by which a patient can be assisted in restoring normal heart rhythm and reducing the onset of arrhythmias.
The current electroporation ablation method is mainly characterized in that abnormal tissues of a patient are positioned through abnormal symptoms of the patient, electric energy is transmitted to the abnormal tissues by using a catheter to generate a high-temperature or low-temperature process for destroying the abnormal tissues, the position of the abnormal tissues is positioned mainly through single-dimensional detection, and the area of the position of the abnormal tissues cannot be accurately positioned for some abnormal tissues without obvious symptoms, so that the electroporation ablation effect on the patient is poor.
Disclosure of Invention
The invention provides an irreversible electroporation ablation method and system with a network-management-shaped support structure, and mainly aims to improve the ablation effect of an ablation support on abnormal tissues of a patient to be ablated.
In order to achieve the above object, the present invention provides an irreversible electroporation ablation method with a mesh-like stent structure, comprising:
Obtaining a venous blood sample of a patient to be ablated, detecting the lipid level of the venous blood sample, analyzing the atherosclerosis risk of the patient to be ablated according to the lipid level, analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery;
detecting the cardiac electrical signal of the patient to be ablated, identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signal, and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the cardiac rhythm;
identifying the atherosclerosis block position and the atherosclerosis block area of the corresponding atherosclerosis block of the patient to be ablated according to the atherosclerosis evaluation report;
according to the atherosclerosis position, a preset ablation stent is utilized to correspondingly drag a guide wire to link with the atherosclerosis to obtain a traction path, the ablation stent is dragged to the atherosclerosis position based on the traction path, and the network management expanding diameter of the ablation stent is determined according to the atherosclerosis area;
When the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, current transmission is carried out on the conductive polar plate corresponding to the ablation support to obtain ablation electric energy, the conductive polar plate is utilized to convert the ablation electric energy into ablation heat energy, and the atherosclerosis is ablated according to the ablation heat energy to obtain an ablation result of the patient to be ablated.
Further, the detecting the lipid level of the venous blood sample comprises:
identifying cholesterol and triglycerides of said venous blood sample;
detecting a cholesterol density of the cholesterol;
classifying the cholesterol into high density lipoprotein cholesterol and low density lipoprotein cholesterol based on the cholesterol density;
detecting the high density cholesterol, the low density cholesterol and the triglyceride content of the venous blood sample respectively;
analyzing the lipid level of the venous blood sample based on the high density cholesterol content, the low density cholesterol content, and the triglyceride content.
Further, the analyzing the risk of atherosclerosis of the patient to be ablated based on the lipid level comprises:
Respectively constructing a high-density cholesterol risk curve, a low-density cholesterol risk curve and a triglyceride risk curve of the lipid level corresponding to the high-density cholesterol content, the low-density cholesterol content and the triglyceride content and the atherosclerosis of the patient to be ablated;
calculating an atherosclerosis risk coefficient of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve and the triglyceride risk curve;
and evaluating the atherosclerosis risk of the patient to be ablated according to the atherosclerosis risk coefficient.
Further, the calculating an atherosclerosis risk factor of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve and the triglyceride risk curve comprises:
calculating an atherosclerosis risk coefficient of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve and the triglyceride risk curve by using the following formula:
A＝(CDD[B]∑ 3 D a θ+E a ω+H a γ)
Wherein A represents an atherosclerosis risk factor, CDD represents a cholesterol density detection model, D a Represents high density cholesterol content, θ represents high density cholesterol risk profile, E a Represents low density cholesterol content, ω represents low density cholesterol risk profile, H a Represents triglyceride content, and gamma represents triglyceride risk profile.
Further, the analyzing the arterial wall thickness, lumen diameter and blood flow velocity of the corresponding artery of the patient to be ablated includes:
carrying out ultrasonic detection on the artery corresponding to the patient to be ablated to obtain an ultrasonic signal;
encoding the ultrasonic signal according to the ultrasonic signal to obtain a digital signal;
based on the digital signals, analyzing the internal arterial structure and blood flow state of the corresponding artery of the patient to be ablated;
based on the internal structure of the artery, analyzing the wall thickness and the lumen diameter of the artery corresponding to the artery of the patient to be ablated;
and identifying the blood flow velocity of the artery corresponding to the patient to be ablated based on the blood flow state.
Further, the constructing an atherosclerosis assessment report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the heart rhythm comprises:
Evaluating, respectively, a risk of atherosclerosis, a characteristic of atherosclerosis, and a cardiac rhythm index of the patient to be ablated for atherosclerosis;
calculating an atherosclerosis value of the patient to be ablated according to the sclerosis risk index, the sclerosis characteristic index and the heart rhythm index;
and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis value.
Further, the calculating the atherosclerosis value of the patient to be ablated according to the sclerosis risk index, the sclerosis characteristic index and the heart rhythm index comprises:
respectively evaluating the hardening risk index, the hardening characteristic index and the heart rhythm index to obtain the hardening risk index weight, the hardening characteristic index weight and the heart rhythm index weight of the atherosclerosis of the patient to be ablated;
analyzing index association relations among the hardening risk indexes, the hardening characteristic indexes and the heart rhythm indexes;
based on the hardening risk index, the hardening feature index, the heart rhythm index, the hardening risk index weight, the hardening feature index weight, the heart rhythm index weight and the index association relation, calculating the atherosclerosis value of the patient to be ablated by using the following formula:
wherein ,indicating atherosclerosis value, J b Represents the hardening risk index, K b Represents the hardening risk index weight, L, corresponding to the hardening risk index c Represents the hardening characteristic index, M c Indicating the weight of the hardening characteristic index corresponding to the hardening characteristic index, U v Represents heart rhythm index, W v Cardiac rhythm index weight indicating cardiac rhythm index correspondence,/->Indicating the index association relationship.
Further, the identifying, according to the atherosclerosis evaluation report, an atherosclerosis mass location and an atherosclerosis mass area of the corresponding atherosclerosis mass of the patient to be ablated includes:
identifying an atherosclerosis image in the atherosclerosis assessment report;
fusing the atherosclerosis images to obtain a hardened fused image;
based on the hardening fusion image, evaluating the hard mass lesion period of the corresponding atherosclerosis hard mass of the patient to be ablated;
determining an atheromatous mass location and an atheromatous mass area of the atheromatous mass based on the atheromatous mass lesion phase and the sclerotic fusion image.
Further, the fusing of the atherosclerosis images to obtain a hardened fused image includes:
Dividing the atherosclerosis image to obtain a high-frequency atherosclerosis image and a low-frequency atherosclerosis image;
fusing the high-frequency atherosclerosis images to obtain fused high-frequency atherosclerosis images;
fusing the low-frequency atherosclerosis images to obtain fused low-frequency atherosclerosis images;
according to the atherosclerosis image, the fusion high-frequency hardening image and the fusion low-frequency hardening image are fused by the following formula to obtain the hardening fusion image:
wherein ,DDRx Representing the x-th hardened fusion image,representing a fusion function, R x Represents the xth fused high frequency hardened image, Z x Represents the xth fused low frequency sclerosis image, Y represents the atherosclerosis image, μ represents the regularization parameters.
In order to solve the above problems, the present invention also provides an irreversible electroporation ablation system having a mesh-like stent structure, the system comprising:
the system comprises a venous blood sample detection module, a control module and a control module, wherein the venous blood sample detection module is used for acquiring a venous blood sample of a patient to be ablated, detecting the lipid level of the venous blood sample, analyzing the atherosclerosis risk of the patient to be ablated according to the lipid level, analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery;
The atherosclerosis evaluation module is used for detecting the cardiac electrical signals of the patient to be ablated, identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signals, and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the cardiac rhythm;
the atherosclerosis positioning module is used for identifying the atherosclerosis position and the atherosclerosis area of the corresponding atherosclerosis of the patient to be ablated according to the atherosclerosis evaluation report;
the ablation support traction module is used for connecting a preset ablation support corresponding traction guide wire with the atherosclerosis according to the atherosclerosis position to obtain a traction path, traction the ablation support to the atherosclerosis position based on the traction path, and determining the network management expansion diameter of the ablation support according to the atherosclerosis area;
and the atherosclerosis ablation module is used for conducting current transmission on the conductive polar plate corresponding to the ablation support when the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, so as to obtain ablation electric energy, converting the ablation electric energy into ablation heat energy by utilizing the conductive polar plate, and performing ablation on the atherosclerosis according to the ablation heat energy, so as to obtain an ablation result of the patient to be ablated.
According to the embodiment of the invention, the lipid level of the venous blood sample can be detected to detect the content of cholesterol, triglyceride and other lipids in blood so as to analyze the lipid state of the patient to be ablated; according to the embodiment of the invention, more accurate quantitative data can be provided by analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the corresponding artery of the patient to be ablated, so that a doctor can be helped to evaluate the lesion degree of the artery; further, according to the embodiment of the invention, by constructing the atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the heart rhythm, the atherosclerosis state of the patient to be ablated can be analyzed through multidimensional diagnosis, so that the accuracy of identifying the atherosclerosis symptoms of the patient to be ablated is improved; according to the embodiment of the invention, the atheroma position and the atheroma area of the atheroma corresponding to the patient to be ablated can be identified according to the atheroma evaluation report, and the exact position coordinates of the atheroma corresponding to the patient to be ablated can be accurately positioned, so that the ablation effect of the ablation support on the atheroma is improved. Therefore, the irreversible electroporation ablation method and system with the mesh-shaped support structure can improve the ablation effect of the ablation support on abnormal tissues of a patient to be ablated.
Drawings
FIG. 1 is a schematic flow chart of an irreversible electroporation ablation method with a mesh-like stent structure according to an embodiment of the present application;
FIG. 2 is a functional block diagram of an irreversible electroporation ablation system with a mesh-like stent structure according to an embodiment of the application;
fig. 3 is a schematic structural diagram of an electronic device with a mesh-like support structure for an irreversible electroporation ablation system according to an embodiment of the application
The achievement of the objects, functional features and advantages of the present application will be further described with reference to the accompanying drawings, in conjunction with the embodiments.
Detailed Description
It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the application.
The embodiment of the application provides an irreversible electroporation ablation method with a network-management-shaped support structure. The execution main body of the irreversible electroporation ablation method with the network-management-shaped support structure comprises at least one of a server, a terminal and the like which can be configured to execute the method provided by the embodiment of the application. In other words, the irreversible electroporation ablation method with the mesh-like scaffold structure may be performed by software or hardware installed in a terminal device or a server device, and the software may be a blockchain platform. The service end includes but is not limited to: a single server, a server cluster, a cloud server or a cloud server cluster, and the like. The server may be an independent server, or may be a cloud server that provides cloud services, cloud databases, cloud computing, cloud functions, cloud storage, network services, cloud communications, middleware services, domain name services, security services, content delivery networks (Content Delivery Network, CDN), and basic cloud computing services such as big data and artificial intelligence platforms.
Referring to fig. 1, a schematic flow chart of an irreversible electroporation ablation method with a mesh-like stent structure according to an embodiment of the invention is shown. In this embodiment, the irreversible electroporation ablation method with a mesh-like stent structure includes:
s1, obtaining a venous blood sample of a patient to be ablated, detecting the lipid level of the venous blood sample, analyzing the atherosclerosis risk of the patient to be ablated according to the lipid level, analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery.
In the embodiment of the present invention, the venous blood sample refers to a blood sample in a vein of the patient to be ablated.
The lipid state of the patient to be ablated can be analyzed by detecting the lipid level of the venous blood sample and detecting the content of cholesterol, triglyceride and other lipids in the blood.
As one embodiment of the present invention, the detecting the lipid level of the venous blood sample comprises: identifying cholesterol and triglycerides of said venous blood sample; detecting a cholesterol density of the cholesterol; classifying the cholesterol into high density lipoprotein cholesterol and low density lipoprotein cholesterol based on the cholesterol density; detecting the high density cholesterol, the low density cholesterol and the triglyceride content of the venous blood sample respectively; analyzing the lipid level of the venous blood sample based on the high density cholesterol content, the low density cholesterol content, and the triglyceride content.
Wherein the cholesterol refers to the total amount of all cholesterol in the venous blood sample, the triglyceride refers to glycerolipid in the venous blood sample, the high-density lipoprotein cholesterol refers to higher-density cholesterol, the low-density lipoprotein cholesterol refers to lower-density cholesterol, and the high-density cholesterol content, the low-density cholesterol content and the triglyceride content refer to the high-density lipoprotein cholesterol, the low-density lipoprotein cholesterol and the triglyceride content in the venous blood sample, respectively.
According to the method and the device, the atherosclerosis risk of the patient to be ablated is analyzed according to the lipid level and can be used as an index for evaluating whether the patient to be ablated has atherosclerosis symptoms, so that the judgment authenticity is improved. Wherein the risk of atherosclerosis refers to the degree of risk of atherosclerosis in the patient to be ablated by analysis of the lipid level.
As an embodiment of the invention, said analyzing the risk of atherosclerosis of said patient to be ablated based on said lipid level comprises: respectively constructing a high-density cholesterol risk curve, a low-density cholesterol risk curve and a triglyceride risk curve of the lipid level corresponding to the high-density cholesterol content, the low-density cholesterol content and the triglyceride content and the atherosclerosis of the patient to be ablated; calculating an atherosclerosis risk coefficient of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve and the triglyceride risk curve; and evaluating the atherosclerosis risk of the patient to be ablated according to the atherosclerosis risk coefficient.
Further, in an embodiment of the present invention, the calculating the atherosclerosis risk factor of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve, and the triglyceride risk curve includes: calculating an atherosclerosis risk coefficient of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve and the triglyceride risk curve by using the following formula:
wherein A represents an atherosclerosis risk factor, CDD represents a cholesterol density detection model, D a Represents high density cholesterol content, θ represents high density cholesterol risk profile, E a Represents low density cholesterol content, ω represents low density cholesterol risk profile, H a Represents triglyceride content, and gamma represents triglyceride risk profile.
Further, the embodiment of the invention can provide more accurate quantitative data by analyzing the wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the artery of the patient to be ablated, so as to help doctors evaluate the lesion degree of the artery. Wherein the arterial wall thickness, the lumen diameter and the blood flow velocity refer to the thickness of the arterial wall, the lumen diameter and the velocity of blood flow of the corresponding artery of the patient to be ablated.
As an embodiment of the present invention, the analyzing the arterial wall thickness, lumen diameter, and blood flow velocity of the corresponding artery of the patient to be ablated includes: carrying out ultrasonic detection on the artery corresponding to the patient to be ablated to obtain an ultrasonic signal; encoding the ultrasonic signal according to the ultrasonic signal to obtain a digital signal; based on the digital signals, analyzing the internal arterial structure and blood flow state of the corresponding artery of the patient to be ablated; based on the internal structure of the artery, analyzing the wall thickness and the lumen diameter of the artery corresponding to the artery of the patient to be ablated; and identifying the blood flow velocity of the artery corresponding to the patient to be ablated based on the blood flow state.
The ultrasonic signals are ultrasonic wave fluctuation signals obtained after ultrasonic detection is carried out on arteries corresponding to a patient to be ablated, the digital signals are signals which can be read by a computer and are obtained by converting the ultrasonic signals into signals which can be read by a computer, the internal structures of the veins are internal structural characteristics of the arteries corresponding to the patient to be ablated, and the blood flow state is the characteristics of blood flow of the arteries corresponding to the patient to be ablated.
Further, in an embodiment of the present invention, the ultrasonic detection of the artery corresponding to the patient to be ablated may be performed by an ultrasonic instrument to obtain an ultrasonic signal.
Further, according to the method, the atherosclerosis characteristics of the patient to be ablated can be analyzed according to the arterial wall thickness of the artery, the lumen diameter and the blood flow velocity, so that the atherosclerosis diagnosis effect of the patient to be ablated can be improved by taking the atherosclerosis characteristics as the basis for diagnosing the atherosclerosis of the patient to be ablated.
As one embodiment of the present invention, the analyzing the characteristic of atherosclerosis of the patient to be ablated based on the arterial wall thickness, the lumen diameter, and the blood flow velocity of the artery may identify an abnormal plaque and an arterial stenosis degree of the artery by the arterial wall thickness and the lumen diameter, and analyze the characteristic of atherosclerosis of the patient to be ablated based on the abnormal plaque, the arterial stenosis degree, and the blood flow velocity. The abnormal plaque is an abnormal plaque growing on the arterial wall of the artery corresponding to the patient to be ablated.
S2, detecting the cardiac electrical signal of the patient to be ablated, identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signal, and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the cardiac rhythm.
The embodiment of the invention can evaluate the electrical activity of the heart by detecting the cardiac electrical signal of the patient to be ablated, and detect whether the heart problems related to atherosclerosis such as myocardial ischemia exist. Wherein the cardiac electrical signal refers to an electrical signal generated by the heart of the patient to be ablated during normal operation.
As one embodiment of the present invention, the detecting cardiac electrical signals of the patient to be ablated includes: marking the pacing cells and conducting tissue of the patient to be ablated; identifying electrical pulses issued by the pacing cells; conducting the electrical pulse to ventricular muscle cells of the patient to be ablated using the conducting tissue; based on the electrical pulse, the ventricular muscle cells control ventricular contraction of the patient to be ablated; and recording the frequency of ventricular contraction to obtain the cardiac electrical signal of the patient to be ablated.
The pacing cells are cells which are used for sending pulse signals in a specific time interval by the patient to be ablated, the conduction tissues are structural tissues which conduct the pulse signals, the electric pulses are pulse electric signals which are sent by the pacing cells in the specific time interval, and the ventricular muscle cells are cells which control ventricular contraction.
Furthermore, the embodiment of the invention can help doctors judge whether cardiac problems such as arrhythmia, myocardial ischemia, ventricular hypertrophy and the like exist or not by identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signals. Wherein the cardiac rhythm refers to a heart beat frequency of the patient to be ablated.
As an embodiment of the present invention, the identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signal may be read by a contraction frequency curve of the patient to be ablated constructed by the cardiac electrical signal.
Further, according to the embodiment of the invention, the atherosclerosis state of the patient to be ablated can be analyzed through multidimensional diagnosis by constructing the atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the heart rhythm, so that the accuracy of identifying the atherosclerosis symptoms of the patient to be ablated is improved. Wherein the atherosclerosis assessment report refers to a report for assessing the atherosclerotic condition of the patient to be ablated.
As an embodiment of the present invention, said constructing an atherosclerosis assessment report of said patient to be ablated based on said atherosclerosis risk, said atherosclerosis characteristics and said heart rhythm comprises: evaluating, respectively, a risk of atherosclerosis, a characteristic of atherosclerosis, and a cardiac rhythm index of the patient to be ablated for atherosclerosis; calculating an atherosclerosis value of the patient to be ablated according to the sclerosis risk index, the sclerosis characteristic index and the heart rhythm index; and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis value.
Wherein the risk of atherosclerosis index, the characteristic of atherosclerosis index and the cardiac rhythm index refer to the risk of atherosclerosis, the characteristic of atherosclerosis and the cardiac rhythm respectively reach the standard of atherosclerosis of the patient to be ablated, and the atherosclerosis value refers to the degree of atherosclerosis of the patient to be ablated.
Further, in an embodiment of the present invention, the calculating the atherosclerosis value of the patient to be ablated according to the risk of sclerosis index, the characteristic of sclerosis index and the cardiac rhythm index includes: respectively evaluating the hardening risk index, the hardening characteristic index and the heart rhythm index to obtain the hardening risk index weight, the hardening characteristic index weight and the heart rhythm index weight of the atherosclerosis of the patient to be ablated; analyzing index association relations among the hardening risk indexes, the hardening characteristic indexes and the heart rhythm indexes; based on the hardening risk index, the hardening feature index, the heart rhythm index, the hardening risk index weight, the hardening feature index weight, the heart rhythm index weight and the index association relation, calculating the atherosclerosis value of the patient to be ablated by using the following formula:
wherein ,indicating atherosclerosis value, J b Represents the hardening risk index, K b Represents the hardening risk index weight, L, corresponding to the hardening risk index c Represents the hardening characteristic index, M c Indicating the weight of the hardening characteristic index corresponding to the hardening characteristic index, U v Represents heart rhythm index, W v Cardiac rhythm index weight indicating cardiac rhythm index correspondence,/->Indicating the index association relationship.
And S3, identifying the atherosclerosis block position and the atherosclerosis block area of the corresponding atherosclerosis block of the patient to be ablated according to the atherosclerosis evaluation report.
According to the atherosclerosis evaluation report, the atherosclerosis block position and the atherosclerosis block area of the patient to be ablated corresponding to the atherosclerosis block are identified, so that the exact position coordinates of the patient to be ablated corresponding to the atherosclerosis block can be accurately positioned, and the ablation effect of the ablation support on the atherosclerosis block is improved. Wherein, the atheromatous mass position and the atheromatous mass area refer to the coordinate position and sweep range of the atheromatous mass in the corresponding artery of the patient to be ablated.
As one embodiment of the present invention, the identifying, according to the atherosclerosis evaluation report, the atherosclerosis location and the atherosclerosis area of the corresponding atherosclerosis of the patient to be ablated includes: identifying an atherosclerosis image in the atherosclerosis assessment report; fusing the atherosclerosis images to obtain a hardened fused image; based on the hardening fusion image, evaluating the hard mass lesion period of the corresponding atherosclerosis hard mass of the patient to be ablated; determining an atheromatous mass location and an atheromatous mass area of the atheromatous mass based on the atheromatous mass lesion phase and the sclerotic fusion image.
The atherosclerosis image refers to an image of atherosclerosis blocks, the atherosclerosis fusion image refers to an image obtained by fusing the atherosclerosis images, the hard block lesion period refers to different lesion periods of the patient to be ablated corresponding to the atherosclerosis blocks, for example, (1) the pattern period is early lesions of atherosclerosis in blood vessels, large spots of needle heads and yellow stripe lesions with different lengths of 1-2 mm appear in the inner films of the arteries, the running of the stripes is parallel to the long axis of the arteries, and a large number of foam cells are gathered at the inner films of the lesions seen under the mirror. (2) The fibrous plaque stage lipid deposition at the intima increases, and the intimal fibrous tissue proliferates and undergoes glass-like degeneration, forming an off-white plaque protruding from the intimal surface, a slightly shiny, wax-like drop, and the thicker fibrous tissue is called fibrous cap. (3) Atheromatous plaque stage, also called atheroma, is formed by fibrous tissue of fibrous plaque being denatured and necrotic, and mixed with lipid. At this time, the lesions become larger and merge with each other and protrude more from the intimal surface. The focus surface is seen under the lens, and thinner fibrous connective tissue is still seen; the deep part is cholesterol crystallization and red-stained necrotic substance; the basal and marginal portions have proliferated shoot tissue and a small amount of foam cells.
Further, in an embodiment of the present invention, the fusing the atherosclerosis image to obtain a hardened fused image includes: dividing the atherosclerosis image to obtain a high-frequency atherosclerosis image and a low-frequency atherosclerosis image; fusing the high-frequency atherosclerosis images to obtain fused high-frequency atherosclerosis images; fusing the low-frequency atherosclerosis images to obtain fused low-frequency atherosclerosis images; according to the atherosclerosis image, the fusion high-frequency hardening image and the fusion low-frequency hardening image are fused by the following formula to obtain the hardening fusion image:
wherein ,DDRx Representing the x-th hardened fusion image,representing a fusion function, R x Represents the xth fused high frequency hardened image, Z x Represents the xth fused low frequency sclerosis image, Y represents the atherosclerosis image, μ represents the regularization parameters.
S4, according to the atherosclerosis position, a preset ablation support is utilized to correspondingly drag a guide wire to be linked with the atherosclerosis to obtain a traction path, the ablation support is dragged to the atherosclerosis position based on the traction path, and the network management expanding diameter of the ablation support is determined according to the atherosclerosis area.
According to the embodiment of the invention, the preset ablation stent is utilized to correspondingly drag the guide wire to link with the atherosclerosis block according to the position of the atherosclerosis block, so that a traction path can be obtained, the ablation stent can be stably dragged into the atherosclerosis block, and the ablation efficiency of the ablation stent on the atherosclerosis block is improved. Wherein the distraction path refers to a path constructed by the distraction guidewire that guides the ablation stent to the site of the atherosclerotic plaque.
According to the invention, the preset ablation stent is used for correspondingly dragging the guide wire to link with the atherosclerosis according to the atherosclerosis position, so that a dragging path can be guided to reach the atherosclerosis position through a vascular system and X-ray or other imaging technologies.
Further, according to the embodiment of the invention, the ablation support is pulled to the atherosclerosis position based on the traction path, so that the ablation support is ensured to be at the specified position of ablation, and the ablation effect on the atherosclerosis is ensured.
Further, according to the embodiment of the invention, the working area of the ablation support can be ensured to meet the elimination requirement of the atherosclerosis by determining the deployment diameter of the network management of the ablation support according to the area of the atherosclerosis. Wherein the expanded diameter of the mesh tube refers to the expanded diameter of the metal mesh structure of the ablation stent.
As one embodiment of the invention, the determining the expanded diameter of the mesh tube of the ablation stent may be by setting the expanded diameter of the mesh tube to be greater than 10% of the length of the area of the atheroma.
And S5, when the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, carrying out current transmission on the conductive polar plate corresponding to the ablation support to obtain ablation electric energy, converting the ablation electric energy into ablation heat energy by utilizing the conductive polar plate, and carrying out ablation on the atherosclerosis according to the ablation heat energy to obtain an ablation result of the patient to be ablated.
According to the embodiment of the invention, when the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, the current transmission is carried out on the conductive polar plate corresponding to the ablation bracket, so that the ablation electric energy is obtained and is used as the original energy for ablating the atherosclerosis, and the ablation energy is ensured. Wherein the ablation electrical energy refers to energy converted from current supplied to the conductive plate.
As an embodiment of the present invention, the current transmission to the conductive electrode plate corresponding to the ablation support may output current through the output end of the pulse electric field generator connected to the tail end interface of the traction wire.
Furthermore, the embodiment of the invention converts the ablation electric energy into the ablation heat energy by using the conductive polar plate, and the generated heat energy can be transferred to the target tissue to destroy or burn the target tissue, thereby realizing the effect of ablation treatment. Wherein, the ablation heat energy refers to heat energy converted from the ablation electric energy.
As one embodiment of the present invention, the electric energy from the ablation is converted into the ablation heat energy by the conductive plate, and the electric current flows inside the conductive plate to generate impedance and resistance, so as to generate the ablation heat energy.
Further, according to the embodiment of the invention, the ablation is performed on the atherosclerosis block according to the ablation heat energy, so that the ablation result of the patient to be ablated can be obtained, and the ablation of the corresponding atherosclerosis block of the patient to be ablated can be completed through the ablation heat energy. The ablation result is obtained after the atherosclerosis is destroyed or burned by the ablation heat energy.
According to the embodiment of the invention, the lipid level of the venous blood sample can be detected to detect the content of cholesterol, triglyceride and other lipids in blood so as to analyze the lipid state of the patient to be ablated; according to the embodiment of the invention, more accurate quantitative data can be provided by analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the corresponding artery of the patient to be ablated, so that a doctor can be helped to evaluate the lesion degree of the artery; further, according to the embodiment of the invention, by constructing the atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the heart rhythm, the atherosclerosis state of the patient to be ablated can be analyzed through multidimensional diagnosis, so that the accuracy of identifying the atherosclerosis symptoms of the patient to be ablated is improved; according to the embodiment of the invention, the atheroma position and the atheroma area of the atheroma corresponding to the patient to be ablated can be identified according to the atheroma evaluation report, and the exact position coordinates of the atheroma corresponding to the patient to be ablated can be accurately positioned, so that the ablation effect of the ablation support on the atheroma is improved. Therefore, the irreversible electroporation ablation method with the mesh-shaped support structure can improve the ablation effect of the ablation support on abnormal tissues of a patient to be ablated.
Fig. 2 is a functional block diagram of an irreversible electroporation ablation system with a mesh-like stent structure according to an embodiment of the invention.
The irreversible electroporation ablation system 200 with a mesh-like stent structure of the present invention can be installed in an electronic device. Depending on the function implemented, the irreversible electroporation ablation system 200 with a mesh-like stent structure can include a venous blood sample detection module 201, an atherosclerosis assessment module 202, an atherosclerosis positioning module 203, an ablation stent traction module 204, and an atherosclerosis ablation module 205. The module of the invention, which may also be referred to as a unit, refers to a series of computer program segments, which are stored in the memory of the electronic device, capable of being executed by the processor of the electronic device and of performing a fixed function.
In the present embodiment, the functions concerning the respective modules/units are as follows:
the venous blood sample detection module 201 is configured to obtain a venous blood sample of a patient to be ablated, detect a lipid level of the venous blood sample, analyze an atherosclerosis risk of the patient to be ablated according to the lipid level, analyze an arterial wall thickness, an lumen diameter and a blood flow velocity of an artery corresponding to the patient to be ablated, and analyze an atherosclerosis characteristic of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery;
The atherosclerosis evaluation module 202 is configured to detect a cardiac electrical signal of the patient to be ablated, identify a cardiac rhythm of the patient to be ablated according to the cardiac electrical signal, and construct an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics, and the cardiac rhythm;
the atherosclerosis positioning module 203 is configured to identify the atherosclerosis position and the atherosclerosis area of the corresponding atherosclerosis of the patient to be ablated according to the atherosclerosis evaluation report;
the ablation support traction module 204 is configured to link the preset ablation support corresponding traction guide wire with the atherosclerosis according to the atherosclerosis position to obtain a traction path, and to traction the ablation support to the atherosclerosis position based on the traction path, and to determine a network management deployment diameter of the ablation support according to the atherosclerosis area;
the atherosclerosis ablation module 205 is configured to perform current transmission on a conductive plate corresponding to the ablation support to obtain ablation electric energy when the deployment diameter of the mesh tube meets the ablation requirement of the atherosclerosis, convert the ablation electric energy into ablation heat energy by using the conductive plate, and perform ablation on the atherosclerosis according to the ablation heat energy to obtain an ablation result of the patient to be ablated.
In detail, each module in the irreversible electroporation ablation system 200 with a mesh-like support structure in the embodiment of the present invention adopts the same technical means as the irreversible electroporation ablation method with a mesh-like support structure in the drawings, and can produce the same technical effects, which are not described herein.
An embodiment of the invention provides an electronic device for implementing an irreversible electroporation ablation method with a mesh-like stent structure.
Referring to fig. 3, the electronic device may include a processor 30, a memory 31, a communication bus 32, and a communication interface 33, and may further include a computer program stored in the memory 31 and executable on the processor 30, such as an irreversible electroporation ablation method program having a mesh-like scaffold structure.
The processor may be formed by an integrated circuit in some embodiments, for example, a single packaged integrated circuit, or may be formed by a plurality of integrated circuits packaged with the same function or different functions, including one or more central processing units (Central Processing Unit, CPU), a microprocessor, a digital processing chip, a graphics processor, a combination of various control chips, and the like. The processor is a Control Unit (Control Unit) of the electronic device, connects various components of the entire electronic device using various interfaces and lines, and executes various functions of the electronic device and processes data by running or executing programs or modules stored in the memory (for example, executing an irreversible electroporation ablation program having a network-like stent structure, etc.), and calling data stored in the memory.
The memory includes at least one type of readable storage medium including flash memory, removable hard disk, multimedia card, card memory (e.g., SD or DX memory, etc.), magnetic memory, magnetic disk, optical disk, etc. The memory may in some embodiments be an internal storage unit of the electronic device, such as a mobile hard disk of the electronic device. The memory may in other embodiments also be an external storage device of the electronic device, such as a plug-in mobile hard disk, a Smart Media Card (SMC), a Secure Digital (SD) Card, a Flash memory Card (Flash Card) or the like, which are provided on the electronic device. Further, the memory may also include both internal storage units and external storage devices of the electronic device. The memory can be used for storing application software installed in the electronic equipment and various data, such as codes based on irreversible electroporation ablation procedures with a network-like support structure, and the like, and can be used for temporarily storing data which are already output or are to be output.
The communication bus may be a peripheral component interconnect standard (Peripheral Component Interconnect, PCI) bus, or an extended industry standard architecture (Extended Industry Standard Architecture, EISA) bus, among others. The bus may be classified as an address bus, a data bus, a control bus, etc. The bus is arranged to enable a connection communication between the memory and at least one processor or the like.
The communication interface is used for communication between the electronic equipment and other equipment, and comprises a network interface and a user interface. Further, the network interface may include a wired interface and/or a wireless interface (e.g., WI-F I interface, bluetooth interface, etc.), typically used to establish a communication connection between the electronic device and other electronic devices. The user interface may be a Display (Display), an input unit such as a Keyboard (Keyboard), and further the user interface may be a standard wired interface, a wireless interface. Further, in some embodiments, the display may be an LED display, a liquid crystal display, a touch-sensitive liquid crystal display, an OLED (Organic Light-Emitting Diode) touch, or the like. The display may also be referred to as a display screen or display unit, as appropriate, for displaying information processed in the electronic device and for displaying a visual user interface.
For example, although not shown, the electronic device may further include a power source (such as a battery) for powering the respective components, and preferably, the power source may be logically connected to the at least one processor through a power management system, so as to perform functions of charge management, discharge management, and power consumption management through the power management system. The power supply may also include one or more of any of a direct current or alternating current power supply, a recharging system, a power failure detection circuit, a power converter or inverter, a power status indicator, and the like. The electronic device may further include various sensors, bluetooth modules, wi-F i modules, etc., which are not described herein.
It should be understood that the embodiments described are for illustrative purposes only and are not limited to this configuration in the scope of the patent application.
The irreversible electroporation ablation procedure with mesh-like scaffold structure stored by the memory in the electronic device is a combination of instructions that, when executed in the processor, can implement:
obtaining a venous blood sample of a patient to be ablated, detecting the lipid level of the venous blood sample, analyzing the atherosclerosis risk of the patient to be ablated according to the lipid level, analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery;
detecting the cardiac electrical signal of the patient to be ablated, identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signal, and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the cardiac rhythm;
identifying the atherosclerosis block position and the atherosclerosis block area of the corresponding atherosclerosis block of the patient to be ablated according to the atherosclerosis evaluation report;
According to the atherosclerosis position, a preset ablation stent is utilized to correspondingly drag a guide wire to link with the atherosclerosis to obtain a traction path, the ablation stent is dragged to the atherosclerosis position based on the traction path, and the network management expanding diameter of the ablation stent is determined according to the atherosclerosis area;
when the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, current transmission is carried out on the conductive polar plate corresponding to the ablation support to obtain ablation electric energy, the conductive polar plate is utilized to convert the ablation electric energy into ablation heat energy, and the atherosclerosis is ablated according to the ablation heat energy to obtain an ablation result of the patient to be ablated.
Specifically, the specific implementation method of the above instruction by the processor may refer to descriptions of related steps in the corresponding embodiment of the drawings, which are not repeated herein.
Further, the electronic device integrated modules/units, if implemented in the form of software functional units and sold or used as stand-alone products, may be stored in a computer readable storage medium. The computer readable storage medium may be volatile or nonvolatile. For example, the computer readable medium may include: any entity or system capable of carrying the computer program code, a recording medium, a U disk, a removable hard disk, a magnetic disk, an optical disk, a computer Memory, a Read-Only Memory (ROM).
The present invention also provides a computer readable storage medium storing a computer program which, when executed by a processor of an electronic device, can implement:
obtaining a venous blood sample of a patient to be ablated, detecting the lipid level of the venous blood sample, analyzing the atherosclerosis risk of the patient to be ablated according to the lipid level, analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery;
detecting the cardiac electrical signal of the patient to be ablated, identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signal, and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the cardiac rhythm;
identifying the atherosclerosis block position and the atherosclerosis block area of the corresponding atherosclerosis block of the patient to be ablated according to the atherosclerosis evaluation report;
according to the atherosclerosis position, a preset ablation stent is utilized to correspondingly drag a guide wire to link with the atherosclerosis to obtain a traction path, the ablation stent is dragged to the atherosclerosis position based on the traction path, and the network management expanding diameter of the ablation stent is determined according to the atherosclerosis area;
When the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, current transmission is carried out on the conductive polar plate corresponding to the ablation support to obtain ablation electric energy, the conductive polar plate is utilized to convert the ablation electric energy into ablation heat energy, and the atherosclerosis is ablated according to the ablation heat energy to obtain an ablation result of the patient to be ablated.

Claims (10)

1. A method of irreversible electroporation ablation having a mesh-like stent structure, the method comprising:
obtaining a venous blood sample of a patient to be ablated, detecting the lipid level of the venous blood sample, analyzing the atherosclerosis risk of the patient to be ablated according to the lipid level, analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery;
detecting the cardiac electrical signal of the patient to be ablated, identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signal, and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the cardiac rhythm;
Identifying the atherosclerosis block position and the atherosclerosis block area of the corresponding atherosclerosis block of the patient to be ablated according to the atherosclerosis evaluation report;
according to the atherosclerosis position, a preset ablation bracket is utilized to correspondingly drag a guide wire to link with the atherosclerosis to obtain a traction path, the ablation bracket is dragged to the atherosclerosis position based on the traction path, and the network management expansion diameter of the ablation bracket is determined according to the atherosclerosis area;
when the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, current transmission is carried out on the conductive polar plate corresponding to the ablation support to obtain ablation electric energy, the conductive polar plate is utilized to convert the ablation electric energy into ablation heat energy, and the atherosclerosis is ablated according to the ablation heat energy to obtain an ablation result of the patient to be ablated.
2. The irreversible electroporation ablation method with mesh-like stent structure of claim 1, wherein said detecting lipid levels of said venous blood sample comprises:
identifying cholesterol and triglycerides of said venous blood sample;
Detecting a cholesterol density of the cholesterol;
classifying the cholesterol into high density lipoprotein cholesterol and low density lipoprotein cholesterol based on the cholesterol density;
detecting the high density cholesterol, the low density cholesterol and the triglyceride content of the venous blood sample respectively;
analyzing the lipid level of the venous blood sample based on the high density cholesterol content, the low density cholesterol content, and the triglyceride content.
3. The irreversible electroporation ablation method with mesh-like stent structure of claim 1, wherein said analyzing the risk of atherosclerosis in said patient to be ablated based on said lipid level comprises:
respectively constructing a high-density cholesterol risk curve, a low-density cholesterol risk curve and a triglyceride risk curve of the lipid level corresponding to the high-density cholesterol content, the low-density cholesterol content and the triglyceride content and the atherosclerosis of the patient to be ablated;
calculating an atherosclerosis risk coefficient of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve and the triglyceride risk curve;
And evaluating the atherosclerosis risk of the patient to be ablated according to the atherosclerosis risk coefficient.
4. The irreversible electroporation ablation method with a mesh tubular stent of claim 3, wherein said calculating an atherosclerosis risk factor for said patient to be ablated from said high density cholesterol content, said low density cholesterol content, said triglyceride content, said high density cholesterol risk curve, a low density cholesterol risk curve, and a triglyceride risk curve comprises:
calculating an atherosclerosis risk coefficient of the patient to be ablated according to the high-density cholesterol content, the low-density cholesterol content, the triglyceride content, the high-density cholesterol risk curve, the low-density cholesterol risk curve and the triglyceride risk curve by using the following formula:
wherein A represents an atherosclerosis risk factor, CDD represents a cholesterol density detection model, D a Represents high density cholesterol content, θ represents high density cholesterol risk profile, E a Represents low density cholesterol content, ω represents low density cholesterol risk profile, H a Represents triglyceride content, and gamma represents triglyceride risk profile.
5. The irreversible electroporation ablation method with mesh-like stent structure of claim 1, wherein said analyzing the arterial wall thickness, lumen diameter, and blood flow velocity of the corresponding artery of the patient to be ablated comprises:
carrying out ultrasonic detection on the artery corresponding to the patient to be ablated to obtain an ultrasonic signal;
encoding the ultrasonic signal according to the ultrasonic signal to obtain a digital signal;
based on the digital signals, analyzing the internal arterial structure and blood flow state of the corresponding artery of the patient to be ablated;
based on the internal structure of the artery, analyzing the wall thickness and the lumen diameter of the artery corresponding to the artery of the patient to be ablated;
and identifying the blood flow velocity of the artery corresponding to the patient to be ablated based on the blood flow state.
6. The irreversible electroporation ablation method with mesh-like stent structure of claim 1, wherein said constructing an atherosclerosis assessment report for said patient to be ablated based on said risk of atherosclerosis, said atherosclerosis characteristics, and said heart rhythm comprises:
evaluating, respectively, a risk of atherosclerosis, a characteristic of atherosclerosis, and a cardiac rhythm index of the patient to be ablated for atherosclerosis;
Calculating an atherosclerosis value of the patient to be ablated according to the sclerosis risk index, the sclerosis characteristic index and the heart rhythm index;
and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis value.
7. The irreversible electroporation ablation method with a mesh-like stent of claim 6, wherein said calculating an atherosclerosis value for the patient to be ablated based on the hardening risk index, the hardening signature index, and the cardiac rhythm index comprises:
respectively evaluating the hardening risk index, the hardening characteristic index and the heart rhythm index to obtain the hardening risk index weight, the hardening characteristic index weight and the heart rhythm index weight of the atherosclerosis of the patient to be ablated;
analyzing index association relations among the hardening risk indexes, the hardening characteristic indexes and the heart rhythm indexes;
based on the hardening risk index, the hardening feature index, the heart rhythm index, the hardening risk index weight, the hardening feature index weight, the heart rhythm index weight and the index association relation, calculating the atherosclerosis value of the patient to be ablated by using the following formula:
wherein ,indicating atherosclerosis value, J b Represents the hardening risk index, K b Represents the hardening risk index weight, L, corresponding to the hardening risk index c Represents the hardening characteristic index, M c Indicating the weight of the hardening characteristic index corresponding to the hardening characteristic index, U v Represents heart rhythm index, W v The heart rhythm index weight corresponding to the heart rhythm index is represented, and θ represents the index association relationship.
8. The irreversible electroporation ablation method with mesh tubular scaffold of claim 7, wherein said identifying the atheromatous plaque location and atheromatous plaque area of the corresponding atheromatous plaque of the patient to be ablated based on the atheromatous assessment report comprises:
identifying an atherosclerosis image in the atherosclerosis assessment report;
fusing the atherosclerosis images to obtain a hardened fused image;
based on the hardening fusion image, evaluating the hard mass lesion period of the corresponding atherosclerosis hard mass of the patient to be ablated;
determining an atheromatous mass location and an atheromatous mass area of the atheromatous mass based on the atheromatous mass lesion phase and the sclerotic fusion image.
9. The irreversible electroporation ablation method with a mesh-like stent of claim 8, wherein said fusing said atherosclerosis images to obtain a hardened fused image comprises:
Dividing the atherosclerosis image to obtain a high-frequency atherosclerosis image and a low-frequency atherosclerosis image;
fusing the high-frequency atherosclerosis images to obtain fused high-frequency atherosclerosis images;
fusing the low-frequency atherosclerosis images to obtain fused low-frequency atherosclerosis images;
according to the atherosclerosis image, the fusion high-frequency hardening image and the fusion low-frequency hardening image are fused by the following formula to obtain the hardening fusion image:
wherein ,DDRx Represents the xth hardened fusion image jtz {Rx} Representing a fusion function, R x Represents the xth fused high frequency hardened image, Z x Represents the xth fused low frequency sclerosis image, Y represents the atherosclerosis image, μ represents the regularization parameters.
10. An irreversible electroporation ablation system having a mesh-like scaffold, for performing the irreversible electroporation ablation method having a mesh-like scaffold of any of claims 1-9, the system comprising:
the system comprises a venous blood sample detection module, a control module and a control module, wherein the venous blood sample detection module is used for acquiring a venous blood sample of a patient to be ablated, detecting the lipid level of the venous blood sample, analyzing the atherosclerosis risk of the patient to be ablated according to the lipid level, analyzing the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery corresponding to the patient to be ablated, and analyzing the atherosclerosis characteristics of the patient to be ablated according to the arterial wall thickness, the lumen diameter and the blood flow velocity of the artery;
The atherosclerosis evaluation module is used for detecting the cardiac electrical signals of the patient to be ablated, identifying the cardiac rhythm of the patient to be ablated according to the cardiac electrical signals, and constructing an atherosclerosis evaluation report of the patient to be ablated according to the atherosclerosis risk, the atherosclerosis characteristics and the cardiac rhythm;
the atherosclerosis positioning module is used for identifying the atherosclerosis position and the atherosclerosis area of the corresponding atherosclerosis of the patient to be ablated according to the atherosclerosis evaluation report;
the ablation support traction module is used for connecting a preset ablation support corresponding traction guide wire with the atherosclerosis according to the atherosclerosis position to obtain a traction path, traction the ablation support to the atherosclerosis position based on the traction path, and determining the network management expansion diameter of the ablation support according to the atherosclerosis area;
and the atherosclerosis ablation module is used for conducting current transmission on the conductive polar plate corresponding to the ablation support when the deployment diameter of the network tube meets the ablation requirement of the atherosclerosis, so as to obtain ablation electric energy, converting the ablation electric energy into ablation heat energy by utilizing the conductive polar plate, and performing ablation on the atherosclerosis according to the ablation heat energy, so as to obtain an ablation result of the patient to be ablated.
CN202311111154.3A 2023-08-30 2023-08-30 Irreversible electroporation ablation method and system with network-management-shaped support structure Active CN116965919B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311111154.3A CN116965919B (en) 2023-08-30 2023-08-30 Irreversible electroporation ablation method and system with network-management-shaped support structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311111154.3A CN116965919B (en) 2023-08-30 2023-08-30 Irreversible electroporation ablation method and system with network-management-shaped support structure

Publications (2)

Publication Number Publication Date
CN116965919A true CN116965919A (en) 2023-10-31
CN116965919B CN116965919B (en) 2024-06-04

Family

ID=88475121

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311111154.3A Active CN116965919B (en) 2023-08-30 2023-08-30 Irreversible electroporation ablation method and system with network-management-shaped support structure

Country Status (1)

Country Link
CN (1) CN116965919B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275594A (en) * 1990-11-09 1994-01-04 C. R. Bard, Inc. Angioplasty system having means for identification of atherosclerotic plaque
US6228109B1 (en) * 1998-08-31 2001-05-08 Lily Chen Tu Methods for treating atherosclerosis and vulnerable plaques
US6669686B1 (en) * 1999-07-20 2003-12-30 Ajoy Inder Singh Method and apparatus for arterial ablation
CN113995497A (en) * 2020-07-28 2022-02-01 伯恩森斯韦伯斯特(以色列)有限责任公司 Automatically perform irreversible electroporation ablation during cardiac refractory
CN114587562A (en) * 2021-12-03 2022-06-07 杭州睿笛生物科技有限公司 A closed-loop control system for pulse ablation
CN217286034U (en) * 2021-11-16 2022-08-26 杭州睿笛生物科技有限公司 Coronary plaque ablation system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275594A (en) * 1990-11-09 1994-01-04 C. R. Bard, Inc. Angioplasty system having means for identification of atherosclerotic plaque
US6228109B1 (en) * 1998-08-31 2001-05-08 Lily Chen Tu Methods for treating atherosclerosis and vulnerable plaques
US6669686B1 (en) * 1999-07-20 2003-12-30 Ajoy Inder Singh Method and apparatus for arterial ablation
CN113995497A (en) * 2020-07-28 2022-02-01 伯恩森斯韦伯斯特(以色列)有限责任公司 Automatically perform irreversible electroporation ablation during cardiac refractory
CN217286034U (en) * 2021-11-16 2022-08-26 杭州睿笛生物科技有限公司 Coronary plaque ablation system
CN114587562A (en) * 2021-12-03 2022-06-07 杭州睿笛生物科技有限公司 A closed-loop control system for pulse ablation

Also Published As

Publication number Publication date
CN116965919B (en) 2024-06-04

Similar Documents

Publication Publication Date Title
JP6684929B2 (en) RELATED DEVICES, SYSTEMS, AND METHODS FOR DETERMINING PULSE WAVE Velocity Using Intravascular Pressure Measurements and External Ultrasound Imaging
US20170027649A1 (en) Efficient treatment of atrial fibrillation using three-dimensional electrical potential model
US20230329620A1 (en) Methods and systems for wavelength mapping cardiac fibrillation and optimizing ablation lesion placement
US10111598B2 (en) System and method for focal source identification
CN107582042A (en) Multiple electro-anatomical maps automatically create
US9883813B2 (en) Focal point identification and mapping
JP2021186686A (en) Local noise identification using coherent algorithm
CN104736046A (en) Systems and methods for numerically evaluating vasculature
US20200367751A1 (en) Detection of rotational activity in cardiac electrophysiology
JP2021194540A (en) Systems and methods for calculating and detecting cardiac mapping annotations for detecting stable arrhythmic heartbeats
CN105559772A (en) Real-time coloring of electrophysiological map
JP2017033227A (en) Biological simulation system, biological simulation method, biological simulation request program, and biological simulation program
CN110227209B (en) Cardiac pacing simulation for arrhythmia modeling
AU2015202144A1 (en) Checking for perforation of the epicardium using magnetic resonance imaging
CN116965919B (en) Irreversible electroporation ablation method and system with network-management-shaped support structure
JP6244724B2 (en) Frequency domain analysis transformation of renal blood flow Doppler signal to determine stress level
Vila et al. Atrial flutter mechanism detection using directed network mapping
JP2021079099A (en) Method for finding abnormal activation in intra-cardiac electrocardiograms
EP4138093A1 (en) Identification of target sites for ventricular tachycardia treatment
Masè et al. A divergence-based approach for the identification of atrial fibrillation focal drivers from multipolar mapping: A computational study
JP2022048128A (en) Local excitement time analysis system
US20240032847A1 (en) Cardiac diagnostic method, non-transitory computer-readable medium and system
EP4311490A1 (en) Method and system for identification of fractionated signals
US20250032035A1 (en) Methods and systems for shaving an anatomical map
Benjamins Optimalisation of Potential Spatio-temporal Dispersion-based Software for Identification of Drivers from Atrial Fibrillation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant